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Crohn's disease (CD) and ulcerative colitis are the principal types of inﬂammatory bowel disease, which
has a bimodal age distribution, with ~10e15% of the affected population older than 60 years. The
management of CD in the elderly population is more complex due to comorbidities, polypharmacy,
impaired mobility, and surgical candidacy criteria. Further difﬁculty exists in the data and experience
from clinical trials, which often exclude the elderly. Therefore, few data are available that directly
compare treatment efﬁcacies in younger and older patients. Recognizing prescribed medications and
natural disease history in this population is the ﬁrst step in preventing complications and improving
quality of care delivered to older individuals with CD. This review focuses on the CD-related treatment,
associated complications, and limitations in the elderly population.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Crohn's disease (CD) and ulcerative colitis (UC), collectively
known as inﬂammatory bowel disease (IBD), are common causes of
chronic gastrointestinal disease in the developed world. The exact
cause of IBD remains unknown, but it is believed to be due to ge-
netic, immune, and environmental factors. One interesting epide-
miological phenomenon is the bimodal age distribution at
diagnosis, whereby a peak in the disease incidence is observed in
the second and third decades of life, followed by a second increase
in the elderly1. The presence of the bimodal peaks suggests a
complex interaction between genes and environmental exposure in
which the former may play a more important role in the young
versus the latter in the elderly2. Approximately 10e15% of patients
at the ﬁrst ﬂare of, and diagnosedwith, IBD are older than 60 years3.
Of them, 50% are diagnosed at age 60e70 years4. Since the preva-
lence of CD peaks in young adults, the speciﬁc problem in the
elderly has received little attention and misdiagnosis is common.re that they have no conﬂicts
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Hospital, Number 92, Section
ang).
tric Emergency & Critical Care Med
es/by-nc-nd/4.0/).2. Epidemiology
Although the incidence and prevalence of IBD are lower in Asia
than in the West, they have rapidly increased in Asia over the past
two to four decades5. UC is currentlymore common than CD in Asia,
but with the increasing incidence and prevalence of CD in Asia, the
reverse is expected to occur in the future. In Western countries, the
incidence of CD is 14.6e17.4 per 100,000 personeyears. An
increasing incidence and prevalence of CD has been reported in
Asia6. According to North American populationebased studies, the
recent annual incidence of CD in patients  60 years is from six to
12 per 100,000 personeyears7,8. In Taiwan, the incidence of CD
increased from 0.19 per 100,000 personeyears in 1998 to 0.24 per
100,000 person-years in 2008. At the time of diagnosis, 17% of
patients with CD are > 60 years. Of them, 52% present with CD in
their 60s, 37% in their 70s, and 11% in their 80s9.
3. Clinical features
CD is a relapsing inﬂammatory disease that mainly affects the
gastrointestinal tract and frequently presents with abdominal pain,
fever, and clinical signs of bowel obstruction or diarrhea with the
passage of blood or mucus10. Many people with CD have symptoms
for years prior to diagnosis. The clinical manifestations of the ﬁrst
ﬂare of CD in elderly patients are less likely to include abdominalicine. Published by Elsevier Taiwan LLC. This is an open access article under the CC
Figure 1. A 83-year-old woman with CD who had chronic inﬂammation with stenosis.
(A) Endoscopy: stenosis and ulcer in the descending colon. (B) Small bowel series:
luminal narrowing with rigidity and thrush ulcer at distal ileum with skip lesion.
Crohn's Disease in the Elderly 127pain, diarrhea, and anemia. More frequent symptoms of elderly
patients include weight loss, bleeding, fever, and paradoxical con-
stipation (Table 1). Patientswith early-onset CD are likely to express
the disease more severely than those with later-onset CD11e13.
Although the mean lag time between symptom onset and the
ﬁrst visit to a general practitioner is considerably shorter in elderly
than young adults (0.2 years vs. 0.6 years, respectively; p < 0.001),
CD is less frequently diagnosed correctly in the elderly than in
young adults (49% vs. 61%, respectively; p < 0.05). Elderly in-
dividuals were more likely to undergo a bowel operation or
resection earlier after symptom onset11. Elderly patients also have a
lower incidence of family history but an incidence of extraintestinal
manifestations similar to that of younger patients12,14. With regard
to disease location, distal colonic CD is more common in older
patients (40% vs. 6%), whereas extensive colonic CD is more com-
mon in younger patients (27% vs. 4%). Diffuse involvement of the
small bowel is uncommon in both groups10. With regard to disease
behavior, the most common is a nonstricturing and nonpenetrating
pattern in the older group15,16. The initial mortality rate in elderly
CD patients is generally similar to that in younger patients11.
4. Diagnosis
The diagnosis of CD is based on a composite of endoscopic,
radiographic, and pathological ﬁndings documenting focal, asym-
metric, transmural, or granulomatous features. The sequence of
diagnostic maneuvers is based on presenting symptoms, physical
ﬁndings, and basic laboratory abnormalities.
4.1. Laboratory investigations
Anemia and thrombocytosis represent the most common
changes in the full blood count examination of patients with CD. C-
reactive protein and erythrocyte sedimentation rate are standard
laboratory surrogates of the acute-phase response to inﬂamma-
tion17. Fecal calprotectin levels are reportedly a predictivemarker of
mucosal healing and could be used as a relapse marker for patients
with CD18. Calprotectin level is age-related, and one study showed
that elderly patients have signiﬁcantly higher concentrations than
younger patients19.
4.2. Endoscopy
Ileocolonoscopy with biopsy is the gold standard for diagnosing
and monitoring patients with CD (Figure 1)20. However, owing to
its invasive nature and cost, endoscopy (especially balloon-assisted
enteroscopy), is not an appropriate tool for screening patients with
CD. Furthermore, adequate colonoscopy preparation is more difﬁ-
cult in the elderly, and colonic preparations have a higher compli-
cation rate owing to ﬂuid shifts and electrolyte disturbances. The
complication rates of colonoscopy, especially perforation, increase
with age. These risks must be balanced against potential beneﬁts
when colonoscopy is performed in the elderly21.Table 1
Comparison of CD symptoms between elderly and younger patients.
Symptoms Young patient Elderly patient
Abdominal pain Common Occasionally
Diarrhea Common Occasionally
Anemia Common Occasionally
Weight loss Occasionally Common
Fever Occasionally Common
Constipation Occasionally Common
Extraintestinal manifestations Same Same
Severity in the initial diagnosis More severe Less severe4.3. Imaging studies
The diagnosis of CD can be made using contrast radiography
(air-contrast barium enema, small bowel follow-through, or
enteroclysis) to conﬁrm disease location and intestinal compli-
cations (Figure 1). Computed tomography enterography and
magnetic resonance enterography have recently been used, and
early evaluation is effective for inspecting small bowel pathol-
ogy in patients with CD22. Several studies provided evidence
that older age is an independent predictor of contrast-induced
nephropathy. The reasons for this are multifactorial but
include a diminished glomerular ﬁltration rate and increased
incidences of coronary artery disease and diabetes mellitus23. In
contrast to computed tomography enterography, magnetic
resonance enterography does not expose patients to ionizing
radiation and intravenous contrast, and it can differentiate be-
tween inﬂammation and ﬁbrosis as the cause of submucosal
inﬂammation24. These advantages may be used to more
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intervention in elderly patients.
5. Treatment
5.1. Pharmacological treatment and side effects in the elderly
Treating elderly patients with CD is difﬁcult. Furthermore,
comorbidities are more common in elderly patients than younger
patients, which often results in a variety of safety concerns.
5.2. Glucocorticosteroids
Glucocorticosteroids have been the mainstay of treatment for
acute CD ﬂare-ups. Patients with moderate to severe CD are treated
with prednisone 40e60 mg daily or budesonide 9 mg daily until
symptom resolution and weight gain resumption (generally
7e28 days)25. The prevalence of corticosteroid resistance or
dependence in elderly patients is estimated at 30%26.
The elderly are especially prone to hypertension, hypokalemia,
hyperglycemia, and mental status changes. Furthermore,
osteoporosis-related fractures are especially common in the elderly
IBD population, approaching a 15% prevalence27. We should
consider lowering or avoiding the need for systemic steroids.
Therapy with corticosteroids requires the initiation of calcium,
vitamin D, and possibly a bisphosphonate to minimize the occur-
rence of complications.
5.3. 5-Aminosalicylate
Oral 5-aminosalicylate is the most common anti-inﬂammatory
drug used to treat mild to moderate CD25. The availability of new
delayed-release mesalazine preparations with the Multi Matrix
System formulation may facilitate compliance and, therefore,
adherence to treatment in the elderly. However, all of the 5-
aminosalicylate drugs currently used to manage IBD are associ-
ated with nephrotoxicity28. Furthermore, patients with IBD are
usually dehydrated during the acute episode because of diarrhea.
Creatinine clearance should be monitored in the elderly every
6e12months during therapy, especially when long-term high-dose
regimens are used.
5.4. Antibiotics
Antibiotics such as metronidazole and ciproﬂoxacin play a pri-
mary role in the treatment of CD. Metronidazole was proven more
effective for ileocolitis and colitis than for isolated ileal disease in
patients with mild to moderate CD22. The side effects of metroni-
dazole include neuropathy as well as the associated nausea and
metallic taste, which may be particularly marked in the elderly.
Ciproﬂoxacin also has central nervous system side effects22.
5.5. Immunosuppressants
Immunosuppressants, speciﬁcally azathioprine and 6-
mercaptopurine, have demonstrated adjunctive beneﬁts when
used with steroids to treat moderate to severe CD, but they may
take up to 4 months to demonstrate a beneﬁt25. It remains to be
determined how to optimize the dose and whether induction of
leukopenia. Therapeutic monitoring of 6-thioguanine metabolites
offers an improved method of ensuring a long-term response29.
Allopurinol reduces the 6-mercaptopurine/azathioprine dose
and avoids nonhepatic adverse drug reactions30. However, it tends
to increase the incidence of myelotoxicity and infection in older
patients. Parenteral methotrexate (MTX) is another commonlyeffective immunomodulatory agent31. Its side effects of bone
marrow suppression, hepatic ﬁbrosis, and alopecia are well
recognized. Folate deﬁciency worsens MTX toxicity; therefore,
supplemental folic acid is required. MTX is excreted renally;
therefore, the lower glomerular ﬁltration rate in the aged popula-
tion will impact its clearance32.
5.6. Biologic agents
Biologic therapy is well recognized as a breakthrough in the
management of patients with moderate to severe CD. The goal of
medical treatment for CD includes improving patient quality of life
while reducing the need for hospitalization and surgery. Mucosal
healing has been a central issue and is the new goal of IBD
treatment33.
There are two mainstream biologic agents approved by the
United States Food and Drug Administration for the treatment of
CD: anti-tumor necrosis factor [anti-TNFdinﬂiximab, adalimumab
(ADA), and certolizumab]; and anti-adhesion molecular therapy
(natalizumab), an efﬁcacious therapeutic option for patients who
do not respond to anti-TNF therapy34.
Anti-TNF can rapidly improve symptoms in patients with re-
fractory luminal CD and achieve long-term healing of the gut mu-
cosa35. However, serious toxicities related to anti-TNF therapies
have emerged. The most concerning are infectious complications,
autoimmune disorders, and the theoretical risk of cancer and
lymphoma36,37. Inﬂiximab is the ﬁrst and most extensively studied
anti-TNF agent. One study of 500 patients showed that three of ﬁve
deaths attributable to inﬂiximab treatment involved patients aged
> 60 years37. Three patients had a malignant disorder related to
inﬂiximab, and all were elderly37.
ADA is an effective therapy for inducing and maintaining
remission in patients with moderate to severe CD38. In Taiwan, ADA
is the only available biologic that could be used for patients with
CD. One multicenter study of 103 Taiwanese patients showed that
adverse events were observed in 9.7% patients receiving ADA
treatment. Six patients (5.8%) had infections, two patients (1.9%)
had tuberculosis, and none had malignancies39.
According to the Food and Drug Administration package insert
for ADA, the frequency of serious infections and malignancies is
higher in elderly patients40. The package insert for inﬂiximab,
however, reports no overall difference in safety in the elderly versus
younger age groups41.
5.7. Colorectal cancer surveillance in the elderly
Several epidemiological studies have demonstrated an
increased risk of colorectal cancer in patients with IBD that is
globally estimated to be two to ﬁve times higher than that in the
general population of the same age group42. Older patients with
comorbidities are at a higher risk of complications following colo-
rectal cancer surgery43. Earlier onset, longer duration of colitis (>
20 years), and more extensive disease are risk factors44. Surveil-
lance guidelines are based on colitis duration, and recommenda-
tions are not different for the elderly. It is recommended that
patients with CD affecting the colon undergo a screening colo-
noscopy 8e10 years after disease onset as well as routine surveil-
lance colonoscopies every 1e2 years42. Colonoscopy in elderly
patients carries a greater risk of complications, lower completion
rates, and higher chance of poor bowel preparation45. The potential
beneﬁts are signiﬁcantly decreased because of shorter life expec-
tancy and greater prevalence of comorbidities in this group. Thus,
screening colonoscopy in elderly patients should be performed
only after careful consideration of the potential beneﬁts and risks as
well as patient preferences45.
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The surgical management of CD should be considered after
aggressive pharmacotherapy failure and unsolvable complications.
The literature supports the concept of the more frequent use of
surgery and recurrence in adolescents with CD compared with
older adults as a result of a higher incidence of small bowel disease
and its associated complications46.
A recent study examining the effect of age on hospital outcomes
revealed that elderly patients were less likely to be hospitalized
with ﬁstulizing or stricturing disease47. This study also showed that
elderly patients who underwent surgery had a longer postoperative
stay and greater hospital charges than younger patients. Recurrence
after bowel resection was reportedly less common in elderly pa-
tients with CD than in younger patients (43% vs. 64%), but when it
occurred, the time to recurrence was signiﬁcantly shorter in the
elderly patients (3.7 years vs. 5.8 years)11. Surgery should not be
denied for elderly patients who require it for the treatment of
serious CD complications. However, the physician and surgeon
must have thorough knowledge of the surgical indications and risks
in older patients.
6. Additional considerations in the elderly
Comorbidities seen in elderly patients were most commonly
cardiovascular disease, pulmonary disease, and diabetes mellitus.
Polypharmacy and complex dosing regimens are common in
elderly patients, which adds to the noncompliance rate and
drugedrug interactions48. One study showed that each elderly
patient with IBD uses a mean of 6.6 drugs49. The use of topical
agents in this group was difﬁcult due to physical limitations and
anal sphincter incompetence. The earlier use of more highly potent
agents for treating CD has become more widely accepted. However,
the underutilization of immunomodulators and biologics may be
associated with poorer outcomes in the elderly49.
Because of common geriatric ailments such as osteoarthritis and
degenerative joint disease, nonsteroidal anti-inﬂammatory drugs
are the most widely prescribed. The use of high-dose nonsteroidal
anti-inﬂammatory drugs is associated with a higher numerical
disease activity index score among patients with CD and colonic
involvement50. Vitamin B12, vitamin D, and iron deﬁciencies
correlated with CD duration in elderly patients.
Many elderly patients with infections present with nonspeciﬁc
clinical symptoms, which may lead to life-threatening diagnostic
and therapeutic delays51. One study showed that the risk of Clos-
tridium difﬁcile infections in patients with IBD who were treated
with corticosteroids was three times higher than that with other
immunosuppressive agents52. Cytomegalovirus infection is com-
mon in humans and can reactivate in response to different stimuli
in immunocompetent hosts, especially in elderly patients with
comorbidities53. Tuberculosis remains one of the most important
infectious diseases worldwide. In Taiwan, considering the de-
mographics, special caution is warranted in the elderly.
Because of the increased risk of infection and its associated
mortality in immunosuppressed patients with IBD, prevention is
fundamental in older patients54. The vaccination status of elderly
patients with IBD is often neglected. Verifying vaccination status
and regularly vaccinating for inﬂuenza, hepatitis B virus, and
pneumococcal disease are critical interventions55.
7. Conclusion
As the population ages, it is likely that clinicians will face
increasingly more elderly patients with CD. CD in the elderly is
different from that in younger adults in some aspects such asdifferential diagnoses, high comorbidity rates, and polypharmacy.
Therapeutic modalities used in younger age groups are also appli-
cable to the elderly population, but great attention needs to be
given to side effects and drug interactions. In recent years, a top-
down treatment strategy for CD (e.g., start with a combination of
biologicals and immunosuppressants and de-escalate if possible)
has been sought in an effort to decrease surgery and hospitalization
rates33. However, given emerging data on the risks of biologics and
immunosuppressants in the elderly, a step-up approach to treating
CD may be better in this group. The recognition of these important
differences and understanding of special issues in the elderly will
improve clinical practice.References
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